Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders …

Behavioral SymptomsSuicideSelf-Injurious Behavior+18 more

~Estimated

~$10 – $675

National Institute of Mental Health (NIMH)NCT06462196

Phase 3

Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting: A Midazolam-controlled Randomized Controlled Trial

This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if n…

Severe DepressionModerate DepressionKetamine+14 more

~Estimated

~$10 – $7,500

Theresa Jacob, PhD, MPHNCT06752759